Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, with Zhejiang Medicine leading the gains at 1.43% and Xinhecheng experiencing the largest decline [1] - The Medical Innovation ETF (516820) has a latest price of 0.36 yuan, with a turnover rate of 0.28% and a transaction volume of 5.138 million yuan during the trading session [1] - Over the past month, the average daily transaction volume of the Medical Innovation ETF reached 62.8359 million yuan, indicating strong market interest [1] Group 2 - Recently, Eli Lilly's drug, Migalastat, received approval from the National Medical Products Administration of China for two formulations to treat moderate to severe active Crohn's disease and ulcerative colitis, marking a significant advancement in targeted therapies for autoimmune diseases in the digestive system [1] - According to CMB International, the pharmaceutical industry is experiencing structural differentiation due to medical insurance cost control and normalized centralized procurement, with resources increasingly concentrating on innovative pharmaceutical and medical device companies with technological barriers [1] - Since Q4 2025, both domestic and foreign institutions have been increasing their positions in the innovative pharmaceutical and medical device supply chain, reflecting a clearer market logic for allocating innovative assets with clinical value and overseas potential [1] Group 3 - The China Securities Pharmaceutical and Medical Device Innovation Index (931484) selects 30 publicly listed companies with good profitability, growth potential, and research innovation capabilities to reflect the overall performance of the pharmaceutical and medical device sector [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, and others, accounting for a total of 63.9% of the index [2]

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]

Group 1: Market Overview - The Hang Seng Index closed down 233 points, or 0.86%, at 27,032 points, after experiencing significant selling pressure throughout the day [3][4] - Major technology stocks dragged the market down, with Meituan, Ctrip, Tencent, Baidu, JD.com, and Alibaba all reporting declines [4] - The total market turnover was HKD 238.7 billion, with a net inflow of HKD 4.567 billion from northbound trading [3] Group 2: Macro & Industry Dynamics - The Hong Kong Monetary Authority emphasized that managing credit risk will be a top priority in 2026, particularly concerning the commercial real estate sector, which accounts for 14% of total outstanding loans [8] - The MPF Authority aims to reduce administrative fees for the "MPF Easy" platform to below 30 basis points next year, with expected reductions of 57% to 65% in fees for the strong MPF plans [7] Group 3: Company News - Wynn Macau reported an adjusted property EBITDAR of USD 1.085 billion for the year ending December, a decrease of 7.7% year-on-year, with operating revenue down 15.73% [12] - Melco International Development reported a net income of USD 60.635 million for the fourth quarter, a significant turnaround from a net loss of USD 20.274 million in the same period last year [13] - Anton Oilfield Services expects a profit of approximately RMB 360 million to RMB 380 million for the year ending December, representing a year-on-year increase of 48.4% to 56.6% [15]

Group 1: Report Investment Rating - No information provided on the industry investment rating Group 2: Core View - Uncertainty in index futures remains high, and attention should be paid to position management [1] Group 3: Summary of Related Catalogs 1. Index Futures Data Tracking - On February 12, the closing prices of the four major index futures contracts showed mixed trends: IF rose 0.07%, IH fell 0.29%, IC rose 1.24%, and IM rose 1% [1] - The total trading volume of index futures increased, indicating that investors' trading enthusiasm has increased. Specifically, the total trading volume of IF increased by 6,363 lots, IH by 2,280 lots, IC by 12,192 lots, and IM by 21,933 lots [2] - In terms of positions, the total positions of IF decreased by 945 lots, IH by 133 lots, while IC increased by 3,605 lots, and IM increased by 4,216 lots [2] 2. Top 20 Member Position Changes - The position changes of the top 20 members in each index futures contract vary. For example, in the IF2602 contract, long positions increased by 1,825 lots with a net change of 82 lots, and short positions increased by 2,886 lots with a net change of 1,042 lots [5] 3. Trend Strength - The trend strength of IF and IH is 1, and that of IC and IM is also 1. The trend strength ranges from -2 to 2, with -2 being the most bearish and 2 the most bullish [6] 4. Important Drivers - Concerns about AI eroding corporate profits led to a sharp decline in the US stock market, causing a broad decline in risk assets. Technology stocks led the decline, with the Nasdaq falling more than 2%, and the Nasdaq Golden Dragon China Index falling 3% [6] - Trump's tariff policies face major uncertainties. The US House of Representatives passed a resolution against Trump's tariff on Canada, and the future of the USMCA also faces significant uncertainties [7] - The Chinese central bank will conduct a 1 - trillion - yuan six - month outright reverse repurchase operation on February 13, with an incremental scale of 500 billion yuan [6] 5. Market Performance - A - shares showed narrow - range fluctuations, with the Shanghai Composite Index rising 0.05% to 4,134.02 points. Power stocks strengthened, while consumer stocks such as film and television, retail, and food underperformed [7] - Hong Kong stocks fluctuated and declined. The Hang Seng Index fell 0.86% to 27,032.54 points, and the Hang Seng Tech Index fell 1.65% to 5,408.98 points [8]

Core Insights - The Shanghai 180 Index (000010) has shown a slight increase of 0.20% as of February 12, 2026, with notable gains from stocks such as Dongfang Electric (+10.00%) and China National Offshore Oil Corporation (+9.98%) [1] - The Shanghai 180 ETF (530280) has experienced a minor decline of 0.16%, currently priced at 1.26 yuan, but has seen a cumulative increase of 1.04% over the past week [1] - The ETF has a Sharpe ratio of 1.91 since its inception, indicating a favorable risk-adjusted return [1] Performance Metrics - The Shanghai 180 ETF has a maximum drawdown of 4.28% year-to-date, with a relative benchmark drawdown of 0.06% [1] - The management fee for the ETF is set at 0.15%, while the custody fee is 0.05% [1] - The tracking error for the ETF over the past three months is 0.019%, reflecting its close alignment with the underlying index [1] Index Composition - The Shanghai 180 Index comprises 180 securities selected for their large market capitalization and liquidity, representing the core performance of Shanghai's listed companies [2] - As of January 30, 2026, the top ten weighted stocks in the index account for 24.85% of the total index weight, including major companies like Zijin Mining and Kweichow Moutai [2] - The top ten stocks by weight include: - Zijin Mining (4.03%) - Kweichow Moutai (4.22%) - China Ping An (2.87%) - Others include Hengrui Medicine, WuXi AppTec, and China Merchants Bank [3]

Industry Overview - The pharmaceutical and biotechnology sector increased by 0.14% this week, ranking 15th among 31 primary industries in the Shenwan index, outperforming the CSI 300 index by 1.47 percentage points, which fell by 1.33% [2] - The medical services sub-sector reported a rise of 1.31%, while traditional Chinese medicine and medical commercial sectors also saw increases of 2.56% and 0.57%, respectively [2] Company Performance - Top-performing companies in the medical services sector included Meidisi (+18.0%), Tongce Medical (+8.1%), and NuoSiGe (+5.7%), while underperformers included Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3] - CXO-related companies experienced significant pullbacks [3] Valuation Metrics - The medical services sector's price-to-earnings (PE) ratio is currently at 34.43X, with a one-year maximum of 41.13X and a minimum of 28.46X; the price-to-book (PB) ratio stands at 3.49X, with a one-year maximum of 4.00X and a minimum of 2.48X [5] - The PE ratio increased by 0.56X and the PB ratio by 0.06X compared to the previous week [5] Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, focusing on pediatric specialties, which marks a significant regulatory advancement for internet healthcare in major cities [6] - This initiative is expected to enhance online medical services and provide new market opportunities for private healthcare providers [6] Investment Recommendations - The report maintains a "buy" rating for the medical services industry, suggesting a focus on high-growth areas such as ADC CDMO and weight-loss drug supply chains, as well as companies with improving profit expectations like Aier Eye Hospital and Dean Diagnostics [7] - The report emphasizes the importance of a multi-tiered payment system and the resilience of medical demand in stabilizing the industry [7]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in treating primary progressive multiple sclerosis (PPMS), marking a significant advancement in the treatment landscape [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with unmet needs in PPMS due to limited treatment options [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial for PPMS included 985 patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11][24]. - The safety profile of Fenebrutinib was comparable to Ocrelizumab, with a similar incidence of adverse events [22][24]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x [35][36]. - Specific segments like chemical pharmaceuticals and biological products have higher valuations, indicating investor confidence in these areas [35][36].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in a Phase III trial for primary progressive multiple sclerosis (PPMS), marking a significant advancement in treatment options for this condition [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with Roche's Ocrevus projected to generate CHF 7 billion in sales by 2025, indicating substantial unmet needs in the PPMS segment [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% and medical services increasing by 1.3% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial included 985 PPMS patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11]. - The trial results suggest potential benefits for upper limb function, reinforcing the viability of BTK inhibitors in MS treatment [3][25]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth over the next few years [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x, indicating a premium valuation for the sector [35][36]. - Within the sector, chemical pharmaceuticals and biological products have higher valuations at 45.18x and 46.09x, respectively [35].

Market Overview - The Hong Kong stock market declined today, influenced by technology stocks, with the Hang Seng Index stopping its three-day rise and barely holding above the 27,000 mark. The index closed down 0.86% or 233.84 points at 27,032.54, with a total turnover of HKD 238.7 billion. The Hang Seng China Enterprises Index fell 1% to 9,175.18, and the Hang Seng Tech Index dropped 1.65% to 5,408.98 [1] Blue Chip Performance - Zijin Mining (601899) (02899) led blue-chip gains, rising 3.45% to HKD 45.02 with a turnover of HKD 4.993 billion, contributing 14.47 points to the Hang Seng Index. Citigroup raised its target price for Zijin's A-shares and H-shares by over 30% due to increased gold and lithium price forecasts and higher gold sales. The target price for Zijin's H-shares was raised from HKD 39 to HKD 51.8, a 32.8% increase [2] - Other notable blue-chip movements included WuXi AppTec (603259) (02359) up 2.91% to HKD 127.5, contributing 2.69 points; Sun Hung Kai Properties (00016) up 2.85% to HKD 133.5, contributing 8.63 points; while Budweiser APAC (01876) fell 5.21% to HKD 7.83, dragging down the index by 1.42 points [2] Sector Highlights - Technology stocks dragged the market lower, with Tencent down over 2% and Alibaba nearly 1%. However, several major companies launched new models, with Zhizhu's flagship model GLM-5 seeing a price increase and its stock rising over 40% to a new high. MINIMAX also rose over 14% [3] - The chip sector saw significant gains, with domestic GPU leader Tianzuo Zhixin and storage chip leader Zhaoyi Innovation both rising over 20%. Optical communication concepts rebounded, with Yangtze Optical Fibre (601869) benefiting from rising fiber prices, increasing over 12% [4] Notable Stock Movements - Zhongyuan Shipping (600026) (01138) surged 8.61% to HKD 17.6, driven by heightened shipping rates due to geopolitical tensions and increased demand for oil transportation [8] - China National Heavy Duty Truck (000951) (03808) reached a new high, rising 5.58% to HKD 42.38, with January heavy truck exports exceeding 16,000 units, marking a historical high [9] - Rebio Biotech (06938) also performed well, increasing 5.26% to HKD 74.05 after announcing a global exclusive licensing agreement with Madrigal Pharmaceuticals for innovative siRNA therapies [9] Company-Specific News - Budweiser APAC reported a revenue of USD 5.764 billion for the year ending December 31, 2025, a decrease of 7.7% year-on-year, with net profit attributable to shareholders down 32.6% to USD 489 million. The company also reported a loss of USD 105 million in the last quarter, compared to a loss of USD 16 million in the same period last year [10]

Market Overview - The Hong Kong stock market declined today, influenced by technology stocks, with the Hang Seng Index closing down 0.86% at 27,032.54 points, marking the end of a three-day rally [1] - The Hang Seng Technology Index fell 1.65% to 5,408.98 points, indicating a weak performance in the tech sector [1] Blue-Chip Stocks Performance - Zijin Mining (02899) led blue-chip gains, rising 3.45% to HKD 45.02, contributing 14.47 points to the Hang Seng Index, following a target price increase by Citigroup of over 30% for both A-shares and H-shares [2] - WuXi AppTec (02359) and Sun Hung Kai Properties (00016) also saw gains of 2.91% and 2.85%, respectively, while Budweiser APAC (01876) and Trip.com Group (09961) faced declines of 5.21% and 3.9% [2] Sector Highlights - The technology sector faced pressure, with Tencent and Alibaba dropping over 2% and nearly 1%, respectively [3][6] - The AI model sector saw significant gains, with Zhizhu (02513) rising 28.68% and MINIMAX-WP (00100) increasing over 14% [3] - The chip sector experienced a notable rise, with Tianzhi Zhixin (09903) and Zhaoyi Innovation (03986) surging over 20% [4] Notable Company Developments - Zhizhu confirmed the launch of its new model GLM-5, which has seen a price increase of at least 30% for subscription packages, while existing subscribers will maintain their current rates [4] - Micron Technology's stock rose significantly in the U.S. market, with a target price increase to USD 450 by Morgan Stanley, reflecting strong demand driven by AI applications [5] Emerging Trends - The gas turbine sector is gaining traction due to a surge in electricity demand in North America, with companies like Harbin Electric (01133) and Dongfang Electric (01072) seeing substantial stock increases [6] - The North American electricity shortage is expected to create investment opportunities across various technologies, including gas turbines and energy storage [6] Company-Specific News - Budweiser APAC reported a revenue decline of 7.7% to USD 5.764 billion for the year ending December 31, 2025, with a significant drop in net profit by 32.6% [9] - China National Heavy Duty Truck (03808) achieved record high exports of over 16,000 heavy trucks in January, marking a 22.5% year-on-year increase in total vehicle sales for 2025 [8]